Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
ATAI
ATAI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ATAI ETF News Today | Earnings, Events & Price Alerts
ATAI News
Helus Pharma Advances Mental Health Drug Development
4d ago
Newsfilter
Helus Pharma Advances Psychedelic Drug Clinical Trials
4d ago
PRnewswire
Significant Milestones in Biotech Sector This Week
4d ago
NASDAQ.COM
AtaiBeckley Reports Positive EMP-01 Trial Results for Social Anxiety Disorder
5d ago
Benzinga
ATAI Reports Positive Results for EMP 01 in Social Anxiety Disorder Study
5d ago
NASDAQ.COM
AtaiBeckley Appoints New CFO Michael Faerm
Feb 19 2026
seekingalpha
AtaiBeckley Provides 2026 Outlook with Accelerated Drug Development Plans
Jan 08 2026
Globenewswire
GH Research Secures FDA Clearance for GH001 Clinical Trial
Jan 05 2026
Benzinga
Organigram Expands Investment in Phylos to $10 Million for Cannabis Genetics
Jan 04 2026
Yahoo Finance
AtaiBeckley Completes Redomiciliation from Netherlands to U.S.
Dec 31 2025
Globenewswire
AtaiBeckley Completes Redomiciliation from Netherlands to U.S.
Dec 31 2025
Newsfilter
AtaiBeckley Joins NASDAQ Biotechnology Index, Strengthening Market Position
Dec 23 2025
Globenewswire
Psychedelic Stocks May Gain from Marijuana Rescheduling, According to Jefferies
Dec 19 2025
SeekingAlpha
Atai Life Sciences N.V. (ATAI) Obtains Patent for Treatment of Social Anxiety Disorder
Dec 18 2025
Yahoo Finance
AtaiBeckley Secures New Patent for EMP-01, Ensuring Exclusivity Until 2043
Dec 11 2025
Newsfilter
Enhanced Strengthens Executive Leadership Team and Board of Directors
Nov 20 2025
Newsfilter
Show More News
